))
Adjuvant and Neoadjuvant Therapy for NSCLC: Who to Treat and With What Agent
Manage episode 407462021 series 3560609
Content provided by Jacqueline Stone and OBR Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jacqueline Stone and OBR Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Listen in as Roy Herbst, MD, PhD, shares with Robert Figlin, MD, how he approaches treatment for patients with early-stage non-small cell lung cancer after the ADAURA and CHECKMATE-816 trials. They discuss different factors that influence use of adjuvant and neoadjuvant treatments, including stage, EGFR mutation status, and PD-L1 status.
111 episodes
Share
